Literature DB >> 6217782

Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.

D E Kuhl, M E Phelps, C H Markham, E J Metter, W H Riege, J Winter.   

Abstract

Patterns of local cerebral glucose utilization were measured with positron emission, computed tomography using the 18F-fluorodeoxyglucose method in 13 patients with Huntington's disease (HD), 15 subjects at risk for HD, and 40 normal control subjects. These data were compared with computed tomographic measures of cerebral atrophy, with age, and with duration and severity of symptoms. The results indicate that in HD there is a characteristic decrease in glucose utilization in the caudate and putamen and that this local hypometabolism appears early and precedes bulk tissue loss. In contrast to patients with senile dementia, in these HD patients glucose utilization typically was normal throughout the rest of the brain, regardless of the severity of symptoms and despite apparent shrinkage of brain tissue. Our results suggest the possibility that the caudate may be hypometabolic in some asymptomatic subjects who are potential carriers of the autosomal dominant gene for HD.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6217782     DOI: 10.1002/ana.410120504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  70 in total

1.  The differential role of premotor frontal cortex and basal ganglia in motor sequence learning: evidence from focal basal ganglia lesions.

Authors:  Cornelia Exner; Janka Koschack; Eva Irle
Journal:  Learn Mem       Date:  2002 Nov-Dec       Impact factor: 2.460

2.  Fear fosters flight: a mechanism for fear contagion when perceiving emotion expressed by a whole body.

Authors:  Beatrice de Gelder; Josh Snyder; Doug Greve; George Gerard; Nouchine Hadjikhani
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-16       Impact factor: 11.205

3.  pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.

Authors:  Myriam M Chaumeil; Julien Valette; Céline Baligand; Emmanuel Brouillet; Philippe Hantraye; Gilles Bloch; Véronique Gaura; Amandine Rialland; Pierre Krystkowiak; Christophe Verny; Philippe Damier; Philippe Remy; Anne-Catherine Bachoud-Levi; Pierre Carlier; Vincent Lebon
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

4.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 5.  PET and movement disorders.

Authors:  D J Brooks; R S Frackowiak
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

6.  Frontal lobe dysfunction associated with glucose hypometabolism in aceruloplasminemia.

Authors:  Hiroaki Miyajima; Yoshitomo Takahashi; Satoshi Kono; Akira Hishida; Kuniko Ishikawa; Masanobu Sakamoto
Journal:  J Neurol       Date:  2005-03-16       Impact factor: 4.849

Review 7.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 8.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

Review 9.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

10.  Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.

Authors:  Nicole M Lewandowski; Yvette Bordelon; Adam M Brickman; Sergio Angulo; Usman Khan; Jordan Muraskin; Erica Y Griffith; Paula Wasserman; Liliana Menalled; Jean Paul Vonsattel; Karen Marder; Scott A Small; Herman Moreno
Journal:  Neurobiol Dis       Date:  2012-12-04       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.